-
1
-
-
82755161992
-
The future of Alzheimer's disease: The next 10 years
-
Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frolich L, et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 2011;95:718-28.
-
(2011)
Prog Neurobiol
, vol.95
, pp. 718-728
-
-
Hampel, H.1
Prvulovic, D.2
Teipel, S.3
Jessen, F.4
Luckhaus, C.5
Frolich, L.6
-
2
-
-
0037135111
-
The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
-
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-6.
-
(2002)
Science
, vol.297
, pp. 353-356
-
-
Hardy, J.1
Selkoe, D.J.2
-
3
-
-
78650403081
-
Reimagining Alzheimer's disease-an age-based hypothesis
-
Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 2010;30:16755-62.
-
(2010)
J Neurosci
, vol.30
, pp. 16755-16762
-
-
Herrup, K.1
-
5
-
-
77954239263
-
Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives
-
Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74.
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 560-574
-
-
Hampel, H.1
Frank, R.2
Broich, K.3
Teipel, S.J.4
Katz, R.G.5
Hardy, J.6
-
7
-
-
84861814820
-
Clinical trial designs for testing biomarker-based personalized therapies
-
LaiTL,LavoriPW, ShihMC, SikicBI. Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 2012;9:141-54.
-
(2012)
Clin Trials
, vol.9
, pp. 141-154
-
-
Lai, T.L.1
Lavori, P.W.2
Shih, M.C.3
Sikic, B.I.4
-
8
-
-
78751692575
-
Anti-Abtherapeutics inAlzheimer's disease: The need for a paradigm shift
-
GoldeTE, Schneider LS,Koo EH.Anti-Abtherapeutics inAlzheimer's disease: the need for a paradigm shift. Neuron 2011;69:203-13.
-
(2011)
Neuron
, vol.69
, pp. 203-213
-
-
Golde, T.E.1
Schneider, L.S.2
Koo, E.H.3
-
9
-
-
79958102380
-
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
-
Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011;121:597-609.
-
(2011)
Acta Neuropathol
, vol.121
, pp. 597-609
-
-
Shaw, L.M.1
Vanderstichele, H.2
Knapik-Czajka, M.3
Figurski, M.4
Coart, E.5
Blennow, K.6
-
10
-
-
66749116755
-
Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
-
Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, et al. Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener 2009;4:19.
-
(2009)
Mol Neurodegener
, vol.4
, pp. 19
-
-
Garcia-Alloza, M.1
Subramanian, M.2
Thyssen, D.3
Borrelli, L.A.4
Fauq, A.5
Das, P.6
-
11
-
-
0036257424
-
The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease
-
Khachaturian ZS. The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging 2002;23:509-11.
-
(2002)
Neurobiol Aging
, vol.23
, pp. 509-511
-
-
Khachaturian, Z.S.1
-
14
-
-
34447322271
-
Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria
-
Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-46.
-
(2007)
Lancet Neurol
, vol.6
, pp. 734-746
-
-
Dubois, B.1
Feldman, H.H.2
Jacova, C.3
Dekosky, S.T.4
Barberger-Gateau, P.5
Cummings, J.6
-
15
-
-
77957951112
-
Revising the definition of Alzheimer's disease: A new lexicon
-
Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger- Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
-
(2010)
Lancet Neurol
, vol.9
, pp. 1118-1127
-
-
Dubois, B.1
Feldman, H.H.2
Jacova, C.3
Cummings, J.L.4
Dekosky, S.T.5
Barberger- Gateau, P.6
-
16
-
-
0021271971
-
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
-
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
-
(1984)
Neurology
, vol.34
, pp. 939-944
-
-
McKhann, G.1
Drachman, D.2
Folstein, M.3
Katzman, R.4
Price, D.5
Stadlan, E.M.6
-
17
-
-
84863224067
-
Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot
-
Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 2012;8:312-36.
-
(2012)
Alzheimers Dement
, vol.8
, pp. 312-336
-
-
Hampel, H.1
Lista, S.2
Khachaturian, Z.S.3
-
18
-
-
79956098248
-
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
-
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92.
-
(2011)
Alzheimers Dement
, vol.7
, pp. 280-292
-
-
Sperling, R.A.1
Aisen, P.S.2
Beckett, L.A.3
Bennett, D.A.4
Craft, S.5
Fagan, A.M.6
-
19
-
-
79956084514
-
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
-
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
-
(2011)
Alzheimers Dement
, vol.7
, pp. 270-279
-
-
Albert, M.S.1
Dekosky, S.T.2
Dickson, D.3
Dubois, B.4
Feldman, H.H.5
Fox, N.C.6
-
20
-
-
79956142378
-
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
-
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
-
(2011)
Alzheimers Dement
, vol.7
, pp. 263-269
-
-
McKhann, G.M.1
Knopman, D.S.2
Chertkow, H.3
Hyman, B.T.4
Jack Jr., C.R.5
Kawas, C.H.6
-
21
-
-
79956090031
-
Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines forAlzheimer's disease
-
Khachaturian ZS. Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines forAlzheimer's disease. AlzheimersDement 2011;7:253-6.
-
(2011)
AlzheimersDement
, vol.7
, pp. 253-256
-
-
Khachaturian, Z.S.1
-
22
-
-
33747386501
-
Diagnosis of Alzheimer's disease: Two-decades of progress
-
Khachaturian ZS. Diagnosis of Alzheimer's disease: two-decades of progress. J Alzheimers Dis 2006;9:409-15.
-
(2006)
J Alzheimers Dis
, vol.9
, pp. 409-415
-
-
Khachaturian, Z.S.1
-
23
-
-
42049121409
-
Amyloid-related biomarkers for Alzheimer's disease
-
Andreasen N, Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr Med Chem 2008;15:766-71.
-
(2008)
Curr Med Chem
, vol.15
, pp. 766-771
-
-
Andreasen, N.1
Zetterberg, H.2
-
24
-
-
79952793175
-
Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
-
Prvulovic D, Hampel H. Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011;49:367-74.
-
(2011)
Clin Chem Lab Med
, vol.49
, pp. 367-374
-
-
Prvulovic, D.1
Hampel, H.2
-
25
-
-
66149084048
-
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
-
Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106:6820-5.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 6820-6825
-
-
Reiman, E.M.1
Chen, K.2
Liu, X.3
Bandy, D.4
Yu, M.5
Lee, W.6
-
26
-
-
67349270965
-
Apolipoprotein e and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy
-
Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10:333-44.
-
(2009)
Nat Rev Neurosci
, vol.10
, pp. 333-344
-
-
Bu, G.1
-
27
-
-
34047272692
-
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease
-
Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007;68:613-8.
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 613-618
-
-
Coon, K.D.1
Myers, A.J.2
Craig, D.W.3
Webster, J.A.4
Pearson, J.V.5
Lince, D.H.6
-
28
-
-
0027407565
-
Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
-
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977-81.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 1977-1981
-
-
Strittmatter, W.J.1
Saunders, A.M.2
Schmechel, D.3
Pericak-Vance, M.4
Enghild, J.5
Salvesen, G.S.6
-
29
-
-
79952812955
-
The effect of apolipoprotein e (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
-
Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med 2011;49:375-83.
-
(2011)
Clin Chem Lab Med
, vol.49
, pp. 375-383
-
-
Leoni, V.1
-
30
-
-
52449089987
-
Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses
-
Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768-78.
-
(2008)
Nat Rev Neurosci
, vol.9
, pp. 768-778
-
-
Bertram, L.1
Tanzi, R.E.2
-
31
-
-
34248190279
-
Ab oligomers - A decade of discovery
-
Walsh DM, Selkoe DJ. Ab oligomers-a decade of discovery. J Neurochem 2007;101:1172-84.
-
(2007)
J Neurochem
, vol.101
, pp. 1172-1184
-
-
Walsh, D.M.1
Selkoe, D.J.2
-
33
-
-
77952870556
-
Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients
-
Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K. Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 2010; 63:326-30.
-
(2010)
Eur Neurol
, vol.63
, pp. 326-330
-
-
Zetterberg, H.1
Tullhog, K.2
Hansson, O.3
Minthon, L.4
Londos, E.5
Blennow, K.6
-
35
-
-
77952542382
-
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease
-
Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010;223:334-46.
-
(2010)
Exp Neurol
, vol.223
, pp. 334-346
-
-
Hampel, H.1
Shen, Y.2
Walsh, D.M.3
Aisen, P.4
Shaw, L.M.5
Zetterberg, H.6
-
36
-
-
71849099881
-
Amyloid beta and APP as biomarkers for Alzheimer's disease
-
Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol 2010;45:23-9.
-
(2010)
Exp Gerontol
, vol.45
, pp. 23-29
-
-
Zetterberg, H.1
Blennow, K.2
Hanse, E.3
-
37
-
-
7444253126
-
Cerebrospinal fluid protein biomarkers for Alzheimer's disease
-
Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25.
-
(2004)
NeuroRx
, vol.1
, pp. 213-225
-
-
Blennow, K.1
-
38
-
-
38049179307
-
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
-
Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008;4:38-48.
-
(2008)
Alzheimers Dement
, vol.4
, pp. 38-48
-
-
Hampel, H.1
Burger, K.2
Teipel, S.J.3
Bokde, A.L.4
Zetterberg, H.5
Blennow, K.6
-
39
-
-
77955761176
-
Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
-
Mitchell AJ, Monge-Argiles JA, Sanchez-Paya J. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Pract Neurol 2010;10:202-7.
-
(2010)
Pract Neurol
, vol.10
, pp. 202-207
-
-
Mitchell, A.J.1
Monge-Argiles, J.A.2
Sanchez-Paya, J.3
-
40
-
-
84856919991
-
Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease
-
Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:1-5.
-
(2012)
Dement Geriatr Cogn Disord
, vol.33
, pp. 1-5
-
-
Ringman, J.M.1
Coppola, G.2
Elashoff, D.3
Rodriguez-Agudelo, Y.4
Medina, L.D.5
Gylys, K.6
-
41
-
-
84869126018
-
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study
-
Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez- Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048-56.
-
(2012)
Lancet Neurol
, vol.11
, pp. 1048-1056
-
-
Reiman, E.M.1
Quiroz, Y.T.2
Fleisher, A.S.3
Chen, K.4
Velez-Pardo, C.5
Jimenez- Del-Rio, M.6
-
42
-
-
84865529158
-
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
-
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
-
(2012)
N Engl J Med
, vol.367
, pp. 795-804
-
-
Bateman, R.J.1
Xiong, C.2
Benzinger, T.L.3
Fagan, A.M.4
Goate, A.5
Fox, N.C.6
-
43
-
-
40549103442
-
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: Original data and mini-review
-
Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, et al. Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord 2008;25:256-65.
-
(2008)
Dement Geriatr Cogn Disord
, vol.25
, pp. 256-265
-
-
Bibl, M.1
Mollenhauer, B.2
Esselmann, H.3
Schneider, M.4
Lewczuk, P.5
Welge, V.6
-
44
-
-
59849101898
-
CSF amyloid-b 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
-
Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, et al. CSF amyloid-b 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl 2008;2:1548-56.
-
(2008)
Proteomics Clin Appl
, vol.2
, pp. 1548-1556
-
-
Bibl, M.1
Lewczuk, P.2
Esselmann, H.3
Mollenhauer, B.4
Klafki, H.W.5
Welge, V.6
-
45
-
-
84863423724
-
Cerebrospinal fluid amyloid-b 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia
-
Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Ruther E, et al. Cerebrospinal fluid amyloid-b 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 2012; 119:805-13.
-
(2012)
J Neural Transm
, vol.119
, pp. 805-813
-
-
Bibl, M.1
Gallus, M.2
Welge, V.3
Esselmann, H.4
Wolf, S.5
Ruther, E.6
-
46
-
-
0037465449
-
CSFAb42 levels correlate with amyloid-neuropathology in a population-based autopsy study
-
Strozyk D, Blennow K, White LR, Launer LJ. CSFAb42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-6.
-
(2003)
Neurology
, vol.60
, pp. 652-656
-
-
Strozyk, D.1
Blennow, K.2
White, L.R.3
Launer, L.J.4
-
47
-
-
33644832047
-
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans
-
Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 2006;59:512-9.
-
(2006)
Ann Neurol
, vol.59
, pp. 512-519
-
-
Fagan, A.M.1
Mintun, M.A.2
Mach, R.H.3
Lee, S.Y.4
Dence, C.S.5
Shah, A.R.6
-
48
-
-
49349092320
-
PET imaging of amyloid deposition in patients with mild cognitive impairment
-
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G,Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-65.
-
(2008)
Neurobiol Aging
, vol.29
, pp. 1456-1465
-
-
Forsberg, A.1
Engler, H.2
Almkvist, O.3
Blomquist, G.4
Hagman, G.5
Wall, A.6
-
49
-
-
62449262536
-
Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
-
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
-
(2009)
Arch Neurol
, vol.66
, pp. 382-389
-
-
Tapiola, T.1
Alafuzoff, I.2
Herukka, S.K.3
Parkkinen, L.4
Hartikainen, P.5
Soininen, H.6
-
50
-
-
79956197854
-
Different CSF b-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease
-
Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer WJ, Trenkwalder C, Bibl M, et al. Different CSF b-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm 2011;118:691-7.
-
(2011)
J Neural Transm
, vol.118
, pp. 691-697
-
-
Mollenhauer, B.1
Esselmann, H.2
Roeber, S.3
Schulz-Schaeffer, W.J.4
Trenkwalder, C.5
Bibl, M.6
-
51
-
-
0042845853
-
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
-
Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 2003;54:263-7.
-
(2003)
Ann Neurol
, vol.54
, pp. 263-267
-
-
Wiltfang, J.1
Esselmann, H.2
Smirnov, A.3
Bibl, M.4
Cepek, L.5
Steinacker, P.6
-
52
-
-
0036182732
-
Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms
-
Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002;13:112-8.
-
(2002)
Dement Geriatr Cogn Disord
, vol.13
, pp. 112-118
-
-
Sjogren, M.1
Davidsson, P.2
Wallin, A.3
Granerus, A.K.4
Grundstrom, E.5
Askmark, H.6
-
53
-
-
0037295255
-
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy
-
Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186-90.
-
(2003)
Mov Disord
, vol.18
, pp. 186-190
-
-
Holmberg, B.1
Johnels, B.2
Blennow, K.3
Rosengren, L.4
-
54
-
-
84876552168
-
Cerebrospinal fluid biomarkers of b-amyloid metabolism in multiple sclerosis
-
Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, et al. Cerebrospinal fluid biomarkers of b-amyloid metabolism in multiple sclerosis. Mult Scler 2013;19:543-52.
-
(2013)
Mult Scler
, vol.19
, pp. 543-552
-
-
Augutis, K.1
Axelsson, M.2
Portelius, E.3
Brinkmalm, G.4
Andreasson, U.5
Gustavsson, M.K.6
-
55
-
-
74549114139
-
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
-
Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009;9:63.
-
(2009)
BMC Neurol
, vol.9
, pp. 63
-
-
Gisslen, M.1
Krut, J.2
Andreasson, U.3
Blennow, K.4
Cinque, P.5
Brew, B.J.6
-
56
-
-
21844448609
-
Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay
-
Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005; 58:147-50.
-
(2005)
Ann Neurol
, vol.58
, pp. 147-150
-
-
Stenh, C.1
Englund, H.2
Lord, A.3
Johansson, A.S.4
Almeida, C.G.5
Gellerfors, P.6
-
57
-
-
34250854262
-
Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid betachaperone in human cerebrospinal fluid
-
Kanekiyo T, Ban T, Aritake K, Huang ZL, Qu WM, Okazaki I, et al. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid betachaperone in human cerebrospinal fluid. Proc Natl Acad Sci U S A 2007;104:6412-7.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 6412-6417
-
-
Kanekiyo, T.1
Ban, T.2
Aritake, K.3
Huang, Z.L.4
Qu, W.M.5
Okazaki, I.6
-
58
-
-
2942737051
-
Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation
-
Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, et al. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004;25:1033-43.
-
(2004)
Neurobiol Aging
, vol.25
, pp. 1033-1043
-
-
Sastre, M.1
Calero, M.2
Pawlik, M.3
Mathews, P.M.4
Kumar, A.5
Danilov, V.6
-
59
-
-
34250819839
-
Intracellular amyloid-beta in Alzheimer's disease
-
LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509.
-
(2007)
Nat Rev Neurosci
, vol.8
, pp. 499-509
-
-
Laferla, F.M.1
Green, K.N.2
Oddo, S.3
-
60
-
-
21844454462
-
Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: More of the same?
-
Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 2005;58:139-42.
-
(2005)
Ann Neurol
, vol.58
, pp. 139-142
-
-
Schoonenboom, N.S.1
Mulder, C.2
Van Kamp, G.J.3
Mehta, S.P.4
Scheltens, P.5
Blankenstein, M.A.6
-
61
-
-
34247384609
-
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment
-
Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:316-20.
-
(2007)
Dement Geriatr Cogn Disord
, vol.23
, pp. 316-320
-
-
Hansson, O.1
Zetterberg, H.2
Buchhave, P.3
Andreasson, U.4
Londos, E.5
Minthon, L.6
-
62
-
-
67651204382
-
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
-
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009;302:385-93.
-
(2009)
JAMA
, vol.302
, pp. 385-393
-
-
Mattsson, N.1
Zetterberg, H.2
Hansson, O.3
Andreasen, N.4
Parnetti, L.5
Jonsson, M.6
-
63
-
-
32544435900
-
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow- up study
-
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow- up study. Lancet Neurol 2006;5:228-34.
-
(2006)
Lancet Neurol
, vol.5
, pp. 228-234
-
-
Hansson, O.1
Zetterberg, H.2
Buchhave, P.3
Londos, E.4
Blennow, K.5
Minthon, L.6
-
64
-
-
16844382811
-
CSFAbeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
-
Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSFAbeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-7.
-
(2005)
Neurology
, vol.64
, pp. 1294-1297
-
-
Herukka, S.K.1
Hallikainen, M.2
Soininen, H.3
Pirttila, T.4
-
65
-
-
3142743789
-
Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment
-
Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-10.
-
(2004)
Mol Psychiatry
, vol.9
, pp. 705-710
-
-
Hampel, H.1
Teipel, S.J.2
Fuchsberger, T.3
Andreasen, N.4
Wiltfang, J.5
Otto, M.6
-
66
-
-
78650413213
-
Diagnosis and biomarkers of predementia in Alzheimer's disease
-
Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010;8:89.
-
(2010)
BMC Med
, vol.8
, pp. 89
-
-
Forlenza, O.V.1
Diniz, B.S.2
Gattaz, W.F.3
-
67
-
-
18444393054
-
Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
-
Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-96.
-
(2002)
J Neurochem
, vol.81
, pp. 481-496
-
-
Wiltfang, J.1
Esselmann, H.2
Bibl, M.3
Smirnov, A.4
Otto, M.5
Paul, S.6
-
68
-
-
82355170154
-
Protein profiling of cerebrospinal fluid
-
Simonsen AH. Protein profiling of cerebrospinal fluid. Methods Mol Biol 2012;818:109-17.
-
(2012)
Methods Mol Biol
, vol.818
, pp. 109-117
-
-
Simonsen, A.H.1
-
69
-
-
0038268072
-
The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: Evidence of a novel carboxyterminally elongated Abeta peptide
-
Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, et al. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003;17:1291-6.
-
(2003)
Rapid Commun Mass Spectrom
, vol.17
, pp. 1291-1296
-
-
Lewczuk, P.1
Esselmann, H.2
Meyer, M.3
Wollscheid, V.4
Neumann, M.5
Otto, M.6
-
70
-
-
12444337654
-
Truncated beta-amyloid peptide species in preclinical Alzheimer's disease as new targets for the vaccination approach
-
Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in preclinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003;85:1581-91.
-
(2003)
J Neurochem
, vol.85
, pp. 1581-1591
-
-
Sergeant, N.1
Bombois, S.2
Ghestem, A.3
Drobecq, H.4
Kostanjevecki, V.5
Missiaen, C.6
-
71
-
-
24144443470
-
Amino-truncated {beta}-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment
-
Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, et al. Amino-truncated {beta}-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650-60.
-
(2005)
Clin Chem
, vol.51
, pp. 1650-1660
-
-
Vanderstichele, H.1
De Meyer, G.2
Andreasen, N.3
Kostanjevecki, V.4
Wallin, A.5
Olsson, A.6
-
72
-
-
33645775230
-
Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry
-
Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 2006;5:1010-6.
-
(2006)
J Proteome Res
, vol.5
, pp. 1010-1016
-
-
Portelius, E.1
Westman-Brinkmalm, A.2
Zetterberg, H.3
Blennow, K.4
-
73
-
-
33750441499
-
An Alzheimer's disease-specific beta amyloid fragment signature in cerebrospinal fluid
-
Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, et al. An Alzheimer's disease-specific beta amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006;409:215-9.
-
(2006)
Neurosci Lett
, vol.409
, pp. 215-219
-
-
Portelius, E.1
Zetterberg, H.2
Andreasson, U.3
Brinkmalm, G.4
Andreasen, N.5
Wallin, A.6
-
74
-
-
36348970121
-
Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry
-
Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007;6:4433-9.
-
(2007)
J Proteome Res
, vol.6
, pp. 4433-4439
-
-
Portelius, E.1
Tran, A.J.2
Andreasson, U.3
Persson, R.4
Brinkmalm, G.5
Zetterberg, H.6
-
75
-
-
77951718059
-
Optimization protocol for amyloid-b peptides detection in human cerebrospinal fluid using SELDI TOF MS
-
Albertini V, Bruno A, Paterlini A, Lista S, Benussi L, Cereda C, et al. Optimization protocol for amyloid-b peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 2010; 4:352-7.
-
(2010)
Proteomics Clin Appl
, vol.4
, pp. 352-357
-
-
Albertini, V.1
Bruno, A.2
Paterlini, A.3
Lista, S.4
Benussi, L.5
Cereda, C.6
-
76
-
-
67649132624
-
Identification of novel APP/Abeta isoforms in human cerebrospinal fluid
-
Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman- Brinkmalm A, Blennow K. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis 2009; 6:87-94.
-
(2009)
Neurodegener Dis
, vol.6
, pp. 87-94
-
-
Portelius, E.1
Brinkmalm, G.2
Tran, A.J.3
Zetterberg, H.4
Westman-Brinkmalm, A.5
Blennow, K.6
-
77
-
-
79955953179
-
A novel pathway for amyloid precursor protein processing
-
Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging 2011;32:1090-8.
-
(2011)
Neurobiol Aging
, vol.32
, pp. 1090-1098
-
-
Portelius, E.1
Price, E.2
Brinkmalm, G.3
Stiteler, M.4
Olsson, M.5
Persson, R.6
-
78
-
-
84860215636
-
Evaluation of the performance of novel Ab isoforms as theragnostic markers in Alzheimer's disease: From the cell to the patient
-
Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K. Evaluation of the performance of novel Ab isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. Neurodegener Dis 2012;10:138-40.
-
(2012)
Neurodegener Dis
, vol.10
, pp. 138-140
-
-
Portelius, E.1
Gustavsson, M.K.2
Zetterberg, H.3
Andreasson, U.4
Blennow, K.5
-
79
-
-
77957257809
-
Acute effect on the Ab isoform pattern in CSF in response to g-secretase modulator and inhibitor treatment in dogs
-
Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, et al. Acute effect on the Ab isoform pattern in CSF in response to g-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-12.
-
(2010)
J Alzheimers Dis
, vol.21
, pp. 1005-1012
-
-
Portelius, E.1
Van Broeck, B.2
Andreasson, U.3
Gustavsson, M.K.4
Mercken, M.5
Zetterberg, H.6
-
80
-
-
77953418604
-
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease
-
Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2010;2:7.
-
(2010)
Alzheimers Res Ther
, vol.2
, pp. 7
-
-
Portelius, E.1
Dean, R.A.2
Gustavsson, M.K.3
Andreasson, U.4
Zetterberg, H.5
Siemers, E.6
-
81
-
-
84865518001
-
Amyloid-b(1-15/16) as a marker for g-secretase inhibition in Alzheimer's disease
-
Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, et al. Amyloid-b(1-15/16) as a marker for g-secretase inhibition in Alzheimer's disease. J Alzheimers Dis 2012;31:335-41.
-
(2012)
J Alzheimers Dis
, vol.31
, pp. 335-341
-
-
Portelius, E.1
Zetterberg, H.2
Dean, R.A.3
Marcil, A.4
Bourgeois, P.5
Nutu, M.6
-
82
-
-
68949192793
-
Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)
-
Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, et al. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009;44:579-85.
-
(2009)
Exp Gerontol
, vol.44
, pp. 579-585
-
-
Buerger, K.1
Frisoni, G.2
Uspenskaya, O.3
Ewers, M.4
Zetterberg, H.5
Geroldi, C.6
-
83
-
-
75149128305
-
Alzheimer's disease and CSF biomarkers: Key challenges for broad clinical applications
-
Mattsson N, Zetterberg H. Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark Med 2009; 3:735-7.
-
(2009)
Biomark Med
, vol.3
, pp. 735-737
-
-
Mattsson, N.1
Zetterberg, H.2
-
84
-
-
77955483685
-
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
-
Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010;6:230-8.
-
(2010)
Alzheimers Dement
, vol.6
, pp. 230-238
-
-
Trojanowski, J.Q.1
Vandeerstichele, H.2
Korecka, M.3
Clark, C.M.4
Aisen, P.S.5
Petersen, R.C.6
-
85
-
-
84873681445
-
A selected reaction monitoring (SRM)-based method for absolute quantification of Ab38, Ab40, and Ab42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls
-
Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Ab38, Ab40, and Ab42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis 2013;33:1021-32.
-
(2013)
J Alzheimers Dis
, vol.33
, pp. 1021-1032
-
-
Pannee, J.1
Portelius, E.2
Oppermann, M.3
Atkins, A.4
Hornshaw, M.5
Zegers, I.6
-
86
-
-
67650149563
-
Future screening for incipient Alzheimer's disease - The influence of prevalence on test performance
-
Mattsson N, Zetterberg H. Future screening for incipient Alzheimer's disease-the influence of prevalence on test performance. Eur Neurol 2009;62:200-3.
-
(2009)
Eur Neurol
, vol.62
, pp. 200-203
-
-
Mattsson, N.1
Zetterberg, H.2
-
87
-
-
79960942624
-
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
-
Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011;34:430-42.
-
(2011)
Trends Neurosci
, vol.34
, pp. 430-442
-
-
Ewers, M.1
Sperling, R.A.2
Klunk, W.E.3
Weiner, M.W.4
Hampel, H.5
-
88
-
-
44649165640
-
Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers
-
Wedeen VJ,Wang RP, Schmahmann JD, Benner T, TsengWY, Dai G, et al. Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers. Neuroimage 2008;41:1267-77.
-
(2008)
Neuroimage
, vol.41
, pp. 1267-1277
-
-
Wedeen, V.J.1
Wang, R.P.2
Schmahmann, J.D.3
Benner, T.4
Tseng, W.Y.5
Dai, G.6
-
89
-
-
79960619279
-
White matter characterization with diffusional kurtosis imaging
-
Fieremans E, Jensen JH, Helpern JA. White matter characterization with diffusional kurtosis imaging. Neuroimage 2011;58:177-88.
-
(2011)
Neuroimage
, vol.58
, pp. 177-188
-
-
Fieremans, E.1
Jensen, J.H.2
Helpern, J.A.3
-
90
-
-
79952806370
-
Anisotropic anomalous diffusion assessed in the human brain by scalar invariant indices
-
De-Santis S, Gabrielli A, Bozzali M, Maraviglia B, Macaluso E, Capuani S. Anisotropic anomalous diffusion assessed in the human brain by scalar invariant indices. Magn Reson Med 2011; 65:1043-52.
-
(2011)
Magn Reson Med
, vol.65
, pp. 1043-1052
-
-
De-Santis, S.1
Gabrielli, A.2
Bozzali, M.3
Maraviglia, B.4
Macaluso, E.5
Capuani, S.6
-
91
-
-
84872093221
-
Alterations in cerebral microstructural integrity in normal aging and in Alzheimer's disease: A multi-contrast diffusion MRI study
-
Seattle, WA
-
Lu H, Jensen JH, Hu C, Falangola MF, Ramani A, Ferris S, et al. Alterations in cerebral microstructural integrity in normal aging and in Alzheimer's disease: a multi-contrast diffusion MRI study. Presented at the 14th Scientific Meeting of the ISMRM, Seattle, WA, 2006. p. 723.
-
(2006)
Presented at the 14th Scientific Meeting of the ISMRM
, pp. 723
-
-
Lu, H.1
Jensen, J.H.2
Hu, C.3
Falangola, M.F.4
Ramani, A.5
Ferris, S.6
-
92
-
-
84862502734
-
Alzheimer disease: New concepts on its neurobiology and the clinical role imaging will play
-
Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263:344-61.
-
(2012)
Radiology
, vol.263
, pp. 344-361
-
-
Jack Jr., C.R.1
-
93
-
-
84864944776
-
CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects
-
Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, et al. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 2012;22:1993-2004.
-
(2012)
Cereb Cortex
, vol.22
, pp. 1993-2004
-
-
Ewers, M.1
Insel, P.2
Jagust, W.J.3
Shaw, L.4
Trojanowski, J.Q.5
Aisen, P.6
-
94
-
-
79958766587
-
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
-
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32:1207-18.
-
(2011)
Neurobiol Aging
, vol.32
, pp. 1207-1218
-
-
Landau, S.M.1
Harvey, D.2
Madison, C.M.3
Koeppe, R.A.4
Reiman, E.M.5
Foster, N.L.6
-
95
-
-
10744232413
-
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
-
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
-
(2004)
Ann Neurol
, vol.55
, pp. 306-319
-
-
Klunk, W.E.1
Engler, H.2
Nordberg, A.3
Wang, Y.4
Blomqvist, G.5
Holt, D.P.6
-
96
-
-
67349227896
-
B amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid
-
Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. b amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiat 2009;65:927-34.
-
(2009)
Biol Psychiat
, vol.65
, pp. 927-934
-
-
Grimmer, T.1
Riemenschneider, M.2
Forstl, H.3
Henriksen, G.4
Klunk, W.E.5
Mathis, C.A.6
-
97
-
-
69449085355
-
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding
-
Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50:1464-70.
-
(2009)
J Nucl Med
, vol.50
, pp. 1464-1470
-
-
Tolboom, N.1
Van Der Flier, W.M.2
Yaqub, M.3
Boellaard, R.4
Verwey, N.A.5
Blankenstein, M.A.6
-
98
-
-
84861198255
-
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
-
Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012; 33:1203-14.
-
(2012)
Neurobiol Aging
, vol.33
, pp. 1203-1214
-
-
Ewers, M.1
Walsh, C.2
Trojanowski, J.Q.3
Shaw, L.M.4
Petersen, R.C.5
Jack Jr., C.R.6
-
99
-
-
79960638062
-
Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors
-
Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One 2011;6:e21896.
-
(2011)
PLoS One
, vol.6
-
-
Cui, Y.1
Liu, B.2
Luo, S.3
Zhen, X.4
Fan, M.5
Liu, T.6
-
100
-
-
80053654021
-
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
-
e19-27
-
Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging 2011; 32:2322.e19-27.
-
(2011)
Neurobiol Aging
, vol.32
, pp. 2322
-
-
Davatzikos, C.1
Bhatt, P.2
Shaw, L.M.3
Batmanghelich, K.N.4
Trojanowski, J.Q.5
-
101
-
-
68249111164
-
MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
-
Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73:294-301.
-
(2009)
Neurology
, vol.73
, pp. 294-301
-
-
Vemuri, P.1
Wiste, H.J.2
Weigand, S.D.3
Shaw, L.M.4
Trojanowski, J.Q.5
Weiner, M.W.6
-
102
-
-
84859394188
-
Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment
-
Schmand B, Eikelenboom P, van Gool WA. Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 2012;29:641-8.
-
(2012)
J Alzheimers Dis
, vol.29
, pp. 641-648
-
-
Schmand, B.1
Eikelenboom, P.2
Van Gool, W.A.3
-
103
-
-
80054765270
-
Alzheimer's Disease Neuroimaging Initiative. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts
-
Schmand B, Eikelenboom P, van Gool WA. Alzheimer's Disease Neuroimaging Initiative. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. J Am Geriatr Soc 2011;59:1705-10.
-
(2011)
J Am Geriatr Soc
, vol.59
, pp. 1705-1710
-
-
Schmand, B.1
Eikelenboom, P.2
Van Gool, W.A.3
-
104
-
-
84864383552
-
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
-
Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012;33:2272-81.
-
(2012)
Neurobiol Aging
, vol.33
, pp. 2272-2281
-
-
Vos, S.1
Van Rossum, I.2
Burns, L.3
Knol, D.4
Scheltens, P.5
Soininen, H.6
-
105
-
-
0344889207
-
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
-
Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-403.
-
(1999)
Neurology
, vol.52
, pp. 1397-1403
-
-
Jack Jr., C.R.1
Petersen, R.C.2
Xu, Y.C.3
O'brien, P.C.4
Smith, G.E.5
Ivnik, R.J.6
-
106
-
-
70350152831
-
Relationships between biomarkers in aging and dementia
-
Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009;73:1193-9.
-
(2009)
Neurology
, vol.73
, pp. 1193-1199
-
-
Jagust, W.J.1
Landau, S.M.2
Shaw, L.M.3
Trojanowski, J.Q.4
Koeppe, R.A.5
Reiman, E.M.6
-
107
-
-
77954981027
-
Comparing predictors of conversion and decline in mild cognitive impairment
-
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-8.
-
(2010)
Neurology
, vol.75
, pp. 230-238
-
-
Landau, S.M.1
Harvey, D.2
Madison, C.M.3
Reiman, E.M.4
Foster, N.L.5
Aisen, P.S.6
-
108
-
-
34247331828
-
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
-
Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070-4.
-
(2007)
Neurobiol Aging
, vol.28
, pp. 1070-1074
-
-
Bouwman, F.H.1
Schoonenboom, S.N.2
Van Der Flier, W.M.3
Van Elk, E.J.4
Kok, A.5
Barkhof, F.6
-
109
-
-
60349119623
-
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease
-
Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, et al. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009;16:351-62.
-
(2009)
J Alzheimers Dis
, vol.16
, pp. 351-362
-
-
Brys, M.1
Glodzik, L.2
Mosconi, L.3
Switalski, R.4
De Santi, S.5
Pirraglia, E.6
-
110
-
-
54149086289
-
Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease
-
Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 2008;64:871-9.
-
(2008)
Biol Psychiatry
, vol.64
, pp. 871-879
-
-
Devanand, D.P.1
Liu, X.2
Tabert, M.H.3
Pradhaban, G.4
Cuasay, K.5
Bell, K.6
-
111
-
-
34249871381
-
FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment
-
Fellgiebel A, Scheurich A, Bartenstein P, Muller MJ. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res 2007;155:167-71.
-
(2007)
Psychiatry Res
, vol.155
, pp. 167-171
-
-
Fellgiebel, A.1
Scheurich, A.2
Bartenstein, P.3
Muller, M.J.4
-
112
-
-
57749091995
-
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease
-
Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009;30:165-73.
-
(2009)
Neurobiol Aging
, vol.30
, pp. 165-173
-
-
Hansson, O.1
Buchhave, P.2
Zetterberg, H.3
Blennow, K.4
Minthon, L.5
Warkentin, S.6
-
113
-
-
77954032616
-
Boosting power for clinical trials using classifiers based on multiple biomarkers
-
Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging 2010;31:1429-42.
-
(2010)
Neurobiol Aging
, vol.31
, pp. 1429-1442
-
-
Kohannim, O.1
Hua, X.2
Hibar, D.P.3
Lee, S.4
Chou, Y.Y.5
Toga, A.W.6
-
114
-
-
84861645859
-
Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion
-
Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage 2012; 62:229-38.
-
(2012)
Neuroimage
, vol.62
, pp. 229-238
-
-
Westman, E.1
Muehlboeck, J.S.2
Simmons, A.3
-
115
-
-
65249092480
-
Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers
-
Hampel H, Broich K. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging 2009;13:373-5.
-
(2009)
J Nutr Health Aging
, vol.13
, pp. 373-375
-
-
Hampel, H.1
Broich, K.2
-
116
-
-
84861195775
-
Gray matter atrophy rate as a marker of disease progression in AD
-
Anderson VM, Schott JM, Bartlett JW, Leung KK, Miller DH, Fox NC. Gray matter atrophy rate as a marker of disease progression in AD. Neurobiol Aging 2012;33:1194-202.
-
(2012)
Neurobiol Aging
, vol.33
, pp. 1194-1202
-
-
Anderson, V.M.1
Schott, J.M.2
Bartlett, J.W.3
Leung, K.K.4
Miller, D.H.5
Fox, N.C.6
-
117
-
-
69249231987
-
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects
-
Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, et al. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage 2009;48:668-81.
-
(2009)
Neuroimage
, vol.48
, pp. 668-681
-
-
Hua, X.1
Lee, S.2
Yanovsky, I.3
Leow, A.D.4
Chou, Y.Y.5
Ho, A.J.6
-
118
-
-
84867502641
-
Enriching amnestic mild cognitive impairment populations for clinical trials: Optimal combination of biomarkers to predict conversion to dementia
-
Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, et al. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis 2012;32:373-85.
-
(2012)
J Alzheimers Dis
, vol.32
, pp. 373-385
-
-
Yu, P.1
Dean, R.A.2
Hall, S.D.3
Qi, Y.4
Sethuraman, G.5
Willis, B.A.6
-
119
-
-
37349026227
-
Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI
-
Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, et al. Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69:2205-12.
-
(2007)
Neurology
, vol.69
, pp. 2205-2212
-
-
Ewers, M.1
Buerger, K.2
Teipel, S.J.3
Scheltens, P.4
Schroder, J.5
Zinkowski, R.P.6
-
120
-
-
84866884848
-
Anatomical MRI and DTI in the diagnosis of Alzheimer's disease: A Europeanmulticenter study
-
Teipel SJ,Wegrzyn M, Meindl T, Frisoni G, Bokde AL, Fellgiebel A, et al. Anatomical MRI and DTI in the diagnosis of Alzheimer's disease: a Europeanmulticenter study. JAlzheimers Dis 2012;31:S33-47.
-
(2012)
JAlzheimers Dis
, vol.31
-
-
Teipel, S.J.1
Wegrzyn, M.2
Meindl, T.3
Frisoni, G.4
Bokde, A.L.5
Fellgiebel, A.6
-
121
-
-
84867528523
-
Indicators of amyloid burden in a populationbased study of cognitively normal elderly
-
Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, et al. Indicators of amyloid burden in a populationbased study of cognitively normal elderly. Neurology 2012; 79:1570-7.
-
(2012)
Neurology
, vol.79
, pp. 1570-1577
-
-
Mielke, M.M.1
Wiste, H.J.2
Weigand, S.D.3
Knopman, D.S.4
Lowe, V.J.5
Roberts, R.O.6
-
122
-
-
84856414697
-
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
-
WeinerMW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2012; 8:S1-68.
-
(2012)
Alzheimers Dement
, vol.8
-
-
Weiner, M.W.1
Veitch, D.P.2
Aisen, P.S.3
Beckett, L.A.4
Cairns, N.J.5
Green, R.C.6
-
123
-
-
77954033765
-
Alzheimer's disease neuroimaging initiative in Europe
-
Frisoni GB. Alzheimer's disease neuroimaging initiative in Europe. Alzheimers Dement 2010;6:280-5.
-
(2010)
Alzheimers Dement
, vol.6
, pp. 280-285
-
-
Frisoni, G.B.1
-
124
-
-
84864533347
-
DSM-5 and clinical trials in psychiatry: Challenges to come?
-
Butlen-Ducuing F, Haas M, Pani L, van Zwieten-Boot B, Broich K. DSM-5 and clinical trials in psychiatry: challenges to come? Nat Rev Drug Discov 2012;11:583-4.
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 583-584
-
-
Butlen-Ducuing, F.1
Haas, M.2
Pani, L.3
Van Zwieten-Boot, B.4
Broich, K.5
-
125
-
-
82755187525
-
Ethical considerations of biomarker use in neurodegenerative diseases - A case study of Alzheimer's disease
-
Prvulovic D, Hampel H. Ethical considerations of biomarker use in neurodegenerative diseases-a case study of Alzheimer's disease. Prog Neurobiol 2011;95:517-9.
-
(2011)
Prog Neurobiol
, vol.95
, pp. 517-519
-
-
Prvulovic, D.1
Hampel, H.2
-
126
-
-
82755197883
-
Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention
-
Trojanowski JQ, Hampel H. Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol 2011;95:491-5.
-
(2011)
Prog Neurobiol
, vol.95
, pp. 491-495
-
-
Trojanowski, J.Q.1
Hampel, H.2
-
127
-
-
82755182821
-
Perspectives of worldwide translational biomarker research in neurodegenerative diseases
-
Nicotera P, Hampel H. Perspectives of worldwide translational biomarker research in neurodegenerative diseases. Prog Neurobiol 2011;95:496-7.
-
(2011)
Prog Neurobiol
, vol.95
, pp. 496-497
-
-
Nicotera, P.1
Hampel, H.2
-
128
-
-
82755197084
-
The role of genetics for biomarker development in neurodegeneration
-
Bertram L, Hampel H. The role of genetics for biomarker development in neurodegeneration. Prog Neurobiol 2011;95:501-4.
-
(2011)
Prog Neurobiol
, vol.95
, pp. 501-504
-
-
Bertram, L.1
Hampel, H.2
-
129
-
-
84868582421
-
Alzheimer disease: From inherited to sporadic AD-crossing the biomarker bridge
-
Hampel H, Lista S. Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 2012;8:598-600.
-
(2012)
Nat Rev Neurol
, vol.8
, pp. 598-600
-
-
Hampel, H.1
Lista, S.2
-
130
-
-
67649628753
-
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study
-
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund- Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-27.
-
(2009)
Lancet Neurol
, vol.8
, pp. 619-627
-
-
Visser, P.J.1
Verhey, F.2
Knol, D.L.3
Scheltens, P.4
Wahlund, L.O.5
Freund- Levi, Y.6
-
131
-
-
84867886105
-
Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease
-
Visser PJ, Vos S, van Rossum I, Scheltens P. Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. Alzheimers Dement 2012;8:560-3.
-
(2012)
Alzheimers Dement
, vol.8
, pp. 560-563
-
-
Visser, P.J.1
Vos, S.2
Van Rossum, I.3
Scheltens, P.4
-
132
-
-
84865085141
-
Alzheimer's disease diagnostic criteria: Practical applications
-
Cummings J. Alzheimer's disease diagnostic criteria: practical applications. Alzheimers Res Ther 2012;4:35.
-
(2012)
Alzheimers Res Ther
, vol.4
, pp. 35
-
-
Cummings, J.1
-
133
-
-
82755161905
-
Biomarkers for Alzheimer's disease therapeutic trials
-
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011;95:579-93.
-
(2011)
Prog Neurobiol
, vol.95
, pp. 579-593
-
-
Hampel, H.1
Wilcock, G.2
Andrieu, S.3
Aisen, P.4
Blennow, K.5
Broich, K.6
|